Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes

What Was Tested

This randomized controlled trial paper looks at Insulin Detemir and NPH Insulin (isophane).

Who Took Part

By PubMed's age tags, the people studied were children, teenagers, adults, middle-aged adults and older adults, both men and women.

This single-center, open-label, randomized, crossover trial included children (aged 6-12 years, n = 13), adolescents (aged 13-17 years, n = 10), and adults (aged 18-65 years, n = 11) of both sexes.

How the Study Was Run

The researchers set it up as a randomized, open-label and crossover study.

The participants were allocated by chance, so the Insulin Detemir group and the comparison group should start out alike.

Everyone knew when Insulin Detemir was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

In the crossover set-up each of the participants took both Insulin Detemir and the comparison in turn, acting as their own control.

Serial blood sampling was performed for 24 h for analysis of serum insulin detemir, human insulin, and glucose concentrations.

What Was Measured

Topics PubMed links to this paper include Age Factors, Carrier Proteins, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin, Insulin Detemir and Insulin, Isophane.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Detemir and NPH Insulin (isophane).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2003 (Diabetes care), a journal based in United States.

More context: the Insulin Detemir compound page and the NPH Insulin (isophane) compound page, all human trials.